Pharmigene is established in 2005 and funded by venture capital firms and individuals. Our goal is to innovate and commercialize diagnostic tests that enable individuals to be better informed about their genomic makeup and to make decisions that better their health. We have licensed exclusive world-wide rights and transferred key know-how from Academia Sinica relating to the genetic markers that are associated with adverse drug reactions caused by several popular drugs. We have obtained ISO 13485 / 9001 and GMP certifications, and are manufacturing our DNA genetic tests under the most stringent guideline. In developing our DNA genetic tests, we also have validated our tests with clinical studies that involved hundreds and thousands of patients. Today our DNA genetic tests are available world wide. Specifically several of our tests have obtained IVD clearance from Department of Health in Taiwan.